GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » EBIT

Medlive Technology Co (HKSE:02192) EBIT : HK$277.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co EBIT?

Medlive Technology Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$164.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$277.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medlive Technology Co's annualized ROC % for the quarter that ended in Dec. 2023 was 26.38%. Medlive Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2,656.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medlive Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 38.47%.


Medlive Technology Co EBIT Historical Data

The historical data trend for Medlive Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co EBIT Chart

Medlive Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 41.50 124.54 86.28 151.39 277.27

Medlive Technology Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.34 40.06 113.23 112.50 164.76

Competitive Comparison of Medlive Technology Co's EBIT

For the Medical Distribution subindustry, Medlive Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlive Technology Co's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medlive Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medlive Technology Co's EV-to-EBIT falls into.



Medlive Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$277.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co  (HKSE:02192) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medlive Technology Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=99.728 * ( 1 - 0.24% )/( (349.737 + 404.511)/ 2 )
=99.4886528/377.124
=26.38 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5340.653 - 231.359 - ( 4826.768 - max(0, 236.08 - 4995.637+4826.768))
=349.737

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5352.753 - 154.411 - ( 4813.606 - max(0, 207.569 - 5001.4+4813.606))
=404.511

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Medlive Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=329.522/( ( (12.699 + max(-130.966, 0)) + (12.114 + max(-70.867, 0)) )/ 2 )
=329.522/( ( 12.699 + 12.114 )/ 2 )
=329.522/12.4065
=2,656.04 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.163 + 0.229 + 0) - (231.359 + 0 + -0.0010000000000048)
=-130.966

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(120.175 + 0.108 + 11.443) - (154.411 + 0 + 48.182)
=-70.867

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medlive Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=277.265/720.724
=38.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlive Technology Co (HKSE:02192) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN
Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.
Executives
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
M3, Inc. 2101 Beneficial owner
Sony Group Corporation 2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng 2101 Beneficial owner
Liu Lingdi 2101 Beneficial owner
Tian Lixin 2101 Beneficial owner
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines